ArticleFrontiers in immunology2026
MRPS28 serves as a biomarker of diagnostic, prognostic, and immune modulation in pan-cancer and promotes breast cancer malignant phenotypes.
Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: MRPS28 (Mitochondrial Ribosomal Protein S28) belongs to the MRP family and plays a critical role in mitochondrial translation and cellular energy metabolism. However, the effect of MRPS28 in pan-cancer remains unknown. This study aimed to perform a comprehensive assessment of the oncogenic potential of MRPS28 in pan-cancer using several databases, with a particular focus on breast cancer. Methods: The Cancer Genome Atlas (TCGA) and Genotype-Tissue Expression (GTEx) databases were employed to evaluate MRPS28 expression across pan-cancer. Furthermore, we analyzed the association between the expression of MRPS28 and diagnosis, prognosis, genetic alterations, genomic heterogeneity, DNA methylation, and immunity. In addition, the biological function of MRPS28 in breast cancer was investigated. The role of MRPS28 in the malignant biological behavior of breast cancer cells was studied through Results: Our analyses indicated that MRPS28 expression dysregulation was noted in various cancer types, and MRPS28 had remarkable diagnostic and prognostic predictive values. MRPS28 expression was substantially related to genetic alterations, genomic heterogeneity, and DNA methylation levels. In addition, MRPS28 was associated with immune infiltration and immune-related gene expression in multiple cancer types. Moreover, our experimental validation confirmed that MRPS28 knockdown considerably suppressed proliferation, migration, and invasion, as well as promoted apoptosis in the breast cancer cell lines MDA-MB-231 and MCF-7. Conclusion: Collectively, these findings imply that MRPS28 emerges as a potential diagnostic and prognostic biomarker across pan-cancer, with a potential oncogenic role in breast cancer progression. Furthermore, it may be a potential therapeutic target for various cancers.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.